Year: 2023
Type: article
Abstract: Glioblastoma (GBM) is the most malignant and lethal brain tumor in adults, with limited therapeutic options and dismal prognosis.Atractylenolide-II (AT-II) is a major bioactive compound from Atractylodes macrocephala Koidz.(Baizhu in Chinese), with anti-inflammatory and anti-tumor activities.However, the anti-tumor effects of AT-II on GBM cells remain unclear.In the present study, the cytotoxicity of AT-II on GBM cells was analyzed using CCK-8 assay, and it revealed that the cell viability was inhibited by AT-II in a dose-dependent manner.The results of Transwell migration assay indicated that AT-II treatment significantly inhibited the cell migration.Furthermore, the cell cycle arrest at G0/G1 phase in AT-II treated cells was presented in the flow cytometry data.Consistently, real-time PCR and western blotting revealed a remarkable decrease of the CCNA and CCNB expression upon AT-II treatment.Moreover, the phosphorylation of both extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) was triggered by AT-II.Collectively, these results suggested that MAPK signaling was involved in AT-II induced cell cycle arrest, contributing to the inhibition of cell viability and migration of GBM cells.
Source: ScienceAsia
Authors: Rui Wang, Tingting Liu, Jiayu Chen, Dianbao Zhang
Institution: China Medical University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4387587039